AR089486A1 - PREPARACION FARMACEUTICA QUE COMPRENDE b-CICLODEXTRINA SUSTITUIDA - Google Patents

PREPARACION FARMACEUTICA QUE COMPRENDE b-CICLODEXTRINA SUSTITUIDA

Info

Publication number
AR089486A1
AR089486A1 ARP120105006A ARP120105006A AR089486A1 AR 089486 A1 AR089486 A1 AR 089486A1 AR P120105006 A ARP120105006 A AR P120105006A AR P120105006 A ARP120105006 A AR P120105006A AR 089486 A1 AR089486 A1 AR 089486A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical preparation
cyclodextrine
replaced
preparation including
compound
Prior art date
Application number
ARP120105006A
Other languages
English (en)
Inventor
Hasegawa Tetsuya
Toyobuku Hidekazu
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47603961&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR089486(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR089486A1 publication Critical patent/AR089486A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Preparación farmacéutica acuosa que comprende 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1H-quinolin-2-ona (compuesto (I)) o una de sus sales, que muestra una mejor solubilidad en agua del compuesto (I) o una de sus sales lograda por adición de b-ciclodextrina sustituida. Preparación farmacéutica que comprende el compuesto (I) o una de sus sales y b-ciclodextrina sustituida.
ARP120105006A 2011-12-28 2012-12-27 PREPARACION FARMACEUTICA QUE COMPRENDE b-CICLODEXTRINA SUSTITUIDA AR089486A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161580708P 2011-12-28 2011-12-28

Publications (1)

Publication Number Publication Date
AR089486A1 true AR089486A1 (es) 2014-08-27

Family

ID=47603961

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120105006A AR089486A1 (es) 2011-12-28 2012-12-27 PREPARACION FARMACEUTICA QUE COMPRENDE b-CICLODEXTRINA SUSTITUIDA

Country Status (20)

Country Link
US (4) US20150005314A1 (es)
EP (1) EP2797631A1 (es)
JP (1) JP6246715B2 (es)
KR (1) KR20140107378A (es)
CN (2) CN104023750A (es)
AR (1) AR089486A1 (es)
AU (1) AU2012360716B2 (es)
BR (1) BR112014015885A8 (es)
CA (1) CA2860282A1 (es)
CL (1) CL2014001754A1 (es)
CO (1) CO7010828A2 (es)
EA (1) EA201491288A1 (es)
HK (1) HK1198939A1 (es)
IL (1) IL233127A0 (es)
MX (1) MX2014007979A (es)
PH (1) PH12014501425A1 (es)
SG (2) SG11201403308QA (es)
TW (1) TW201332572A (es)
WO (1) WO2013100204A1 (es)
ZA (1) ZA201405039B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
US9675051B2 (en) * 2014-07-21 2017-06-13 Nicholas Jay Bonge, JR. Wireless animal training, monitoring and remote control system
JP6513461B2 (ja) * 2015-04-14 2019-05-15 帝國製薬株式会社 ブレクスピプラゾールの経皮吸収製剤
CN105078910B (zh) * 2015-09-22 2018-05-22 成都欣捷高新技术开发有限公司 一种含有依匹哌唑的冻干口服制剂及其制备方法
EP3545950A1 (en) 2018-03-26 2019-10-02 Adamed sp. z o.o. Pharmaceutical composition comprising brexpiprazole
CN115252585A (zh) * 2021-04-13 2022-11-01 上海博志研新药物技术有限公司 一种布瑞哌唑口溶膜包合物、其制备方法及应用
CN115192549A (zh) * 2021-04-13 2022-10-18 上海博志研新药物技术有限公司 一种布瑞哌唑物口腔薄膜剂、其制备方法及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US580708A (en) 1897-04-13 Robert orme
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
JPH10194996A (ja) 1996-12-25 1998-07-28 Janssen Pharmaceut Nv アシル化シクロデキストリン含有製薬組成物
TWI307626B (en) * 2002-08-20 2009-03-21 Bristol Myers Squibb Co Aripiprazole complex formulation and method
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
AR085840A1 (es) * 2011-04-05 2013-10-30 Otsuka Pharma Co Ltd Medicamento que contiene un compuesto que es 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona
JO3227B1 (ar) * 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان

Also Published As

Publication number Publication date
US20180008599A1 (en) 2018-01-11
CO7010828A2 (es) 2014-07-31
AU2012360716B2 (en) 2017-08-17
HK1198939A1 (en) 2015-06-19
US20150005314A1 (en) 2015-01-01
SG11201403308QA (en) 2014-07-30
CN107261153A (zh) 2017-10-20
AU2012360716A1 (en) 2014-07-31
KR20140107378A (ko) 2014-09-04
US20160310617A1 (en) 2016-10-27
EA201491288A1 (ru) 2014-11-28
CN104023750A (zh) 2014-09-03
MX2014007979A (es) 2014-08-21
CA2860282A1 (en) 2013-07-04
JP6246715B2 (ja) 2017-12-13
NZ626379A (en) 2015-09-25
CL2014001754A1 (es) 2014-10-03
WO2013100204A1 (en) 2013-07-04
TW201332572A (zh) 2013-08-16
JP2015503501A (ja) 2015-02-02
ZA201405039B (en) 2015-12-23
BR112014015885A8 (pt) 2017-07-04
EP2797631A1 (en) 2014-11-05
US20170151237A1 (en) 2017-06-01
BR112014015885A2 (pt) 2017-06-13
SG10201605188UA (en) 2016-07-28
PH12014501425A1 (en) 2014-09-22
IL233127A0 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
CL2016001458A1 (es) Derivado de sulfonamida o sales de adición de ácido farmaceuticamente aceptables del mismo.
AR089486A1 (es) PREPARACION FARMACEUTICA QUE COMPRENDE b-CICLODEXTRINA SUSTITUIDA
UY36315A (es) COMPUESTOS NOVEDOSOS ANTAGONISTAS DE INTEGRINA avß6.
CO6950480A2 (es) Tableta que contiene 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona o una de sus sales
EA201400838A1 (ru) ЗАМЕЩЕННЫЕ АМИДИНОМ β-ЛАКТАМЫ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В КАЧЕСТВЕ АНТИБАКТЕРИАЛЬНЫХ СРЕДСТВ
UY32535A (es) Métodos e intermediarios para la preparación de agentes farmacéuticos
BR112014027814A2 (pt) agentes sinérgicos antimicrobianos.
CL2014000393A1 (es) Compuestos derivados de benzofurano y sus sales, como inhibidores del virus de hepatitis c; composicion farmaceutica que los comprende; y su uso para el tratamiento o la prevencion de una infeccion por el virus de hepatitis c o de una enfermedad asociada con dicha infeccion.
CL2018001067A1 (es) Compuesto piranodipiridínico.
CR20160073A (es) Compuestos plaguicidas
UA113086C2 (xx) Піразольні сполуки як інгібітори sglt1
CL2017000230A1 (es) Composición adhesiva
BR112015004825A2 (pt) composição microbicida aquosa.
IT1402651B1 (it) Concentrato per sospensione acquosa di pesticida.
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
UY34916A (es) "preparación sólida que contiene ácido[(3s)-6-){2´,6´-dimetil-4´-[3-(metilsulfonil)propoxi]bifenil-3-il}metoxi)-2,3-dihidro-1-benzofuran-3-il]acético"
ES2571452T3 (es) Compuesto antagonista de leucotrieno B4
CY1119540T1 (el) Υποκατασταθεντα απο γλυκοπυρανοσυλιο παραγωγα ινδολο-ουριας και η χρηση τους ως αναστολεις sglt
CL2014002033A1 (es) Compuestos derivados de dihidrofurano-azetidina y sus sales; composicion farmaceutica o veterinaria que los comprende; y su uso para tratar una infeccion o infestacion parasitaria.
AR092627A1 (es) Derivados glucopiranosidos de urea
CO6670582A2 (es) Compuesto de piridina sustituida que tiene actividad de inhibición de cetp
TH173507A (th) อนุพันธ์ชนิดวงเชื่อมของไดไฮโดรไพริมิโดในฐานะสารยับยั้ง hbv
TH158311A (es)
UA107105U (uk) Спосіб одержання 2-(2-оксотіазолідин-4-іліденеаміно)бензоатної кислоти
TH159388A (th) สารประกอบแมคโครไซคลิคและวิธีการผลิตของมัน

Legal Events

Date Code Title Description
FB Suspension of granting procedure